BRIEF published on 04/24/2025 at 14:05, 1 year 3 months ago Pentixapharm Signs Manufacturing Deal for Yttrium-90 Therapy Clinical Trials Eckert & Ziegler Radiopharmaceuticals Pentixapharm Yttrium-90
BRIEF published on 04/24/2025 at 14:05, 1 year 3 months ago Pentixapharm signe un accord de fabrication pour la thérapie à l'yttrium-90 Eckert & Ziegler Essais Cliniques Produits Radiopharmaceutiques Pentixapharm Yttrium-90
PRESS RELEASE published on 04/24/2025 at 14:00, 1 year 3 months ago Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE Pentixapharm signs manufacturing agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE to produce CXCR4-targeting radiotherapeutic doses for clinical trials Clinical Trials Eckert & Ziegler SE Pentixapharm Y90-PentixaTher Radiotherapeutic
BRIEF published on 04/15/2025 at 08:22, 1 year 3 months ago Pentixapharm Holding AG Reports 2024 Financial Results and 2025 Outlook Research And Development Financial Results 2024 2025 Financial Forecast Radiopharmaceutical Innovation Pentixapharm Strategy
BRIEF published on 04/15/2025 at 08:22, 1 year 3 months ago Pentixapharm Holding AG publie ses résultats financiers pour 2024 et ses perspectives pour 2025 Recherche Et Développement Résultats Financiers 2024 Prévisions Financières 2025 Innovation Radiopharmaceutique Stratégie Pentixapharm
PRESS RELEASE published on 04/15/2025 at 08:17, 1 year 3 months ago Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year Pentixapharm Holding AG releases 2024 financial results with EUR 12.8 million net loss and guides for EUR 23.5 million loss in 2025, focusing on R&D and operating expenses Financial Results 2024 Net Loss 2025 Pentixapharm
BRIEF published on 03/03/2025 at 14:43, 1 year 5 months ago Pentixapharm Holding AG Announces Board Changes Supervisory Board Board Changes Leadership Transition Pentixapharm Governance Dr. Andreas Eckert
BRIEF published on 03/03/2025 at 14:43, 1 year 5 months ago Pentixapharm Holding AG annonce des changements au sein de son conseil d'administration Conseil De Surveillance Transition De Direction Changements Au Sein Du Conseil D'administration Dr. Andreas Eckert Gouvernance De Pentixapharm
PRESS RELEASE published on 03/03/2025 at 14:38, 1 year 5 months ago Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG Personnel changes in both the Supervisory Board and Management Board of Pentixapharm Holding AG have been implemented as of March 1, 2025, aligning the boards of the parent and subsidiary companies Supervisory Board Management Board Berlin Personnel Changes Pentixapharm Holding AG
BRIEF published on 02/13/2025 at 14:15, 1 year 5 months ago Pentixapharm to Present Pioneering Bladder Cancer Treatment at ASCO-GU 2025 Bladder Cancer Lu177-PentixaTher CXCR4 Target ASCO-GU 2025 Radioligand Therapy
Published on 08/10/2026 at 08:00, 2 hours 33 minutes ago Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 33 minutes ago Results of AGM and Management Update Presentation
Published on 08/07/2026 at 23:15, 2 days 11 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/10/2026 at 10:12, 20 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 08/10/2026 at 10:10, 22 minutes ago Hana Bank Subsidiary GLN Expands QR Payment Network for International Travelers to Korea
Published on 08/10/2026 at 09:50, 43 minutes ago Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 33 minutes ago Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 33 minutes ago Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:22, 1 hour 10 minutes ago Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 1 hour 10 minutes ago Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 33 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 33 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
